









Markets
/
Stocks
/
nasdaq-pbmww
/

Psyence Biomedical Ltd

PBMWW

View Detailed Chart

0.025USD

-0.000-1.18%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



Psyence Biomedical Ltd

0.025

-0.000-1.18%

Overview Company Financials

Financials

Intraday

30m

Today

-1.18%

5 Days

-21.74%

1 Month

+38.46%

6 Months

+7.69%

Year to Date

+75.00%

1 Year

+75.00%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(3)

Neutral(3)

Buy(6)

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.000

Buy

RSI(14)

51.438

Neutral

STOCH(KDJ)(9,3,3)

53.400

Sell

ATR(14)

0.008

High Vlolatility

CCI(14)

25.415

Neutral

Williams %R

53.716

Neutral

TRIX(12,20)

2.147

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.030

Sell

MA10

0.029

Sell

MA20

0.024

Buy

MA50

0.021

Buy

MA100

0.018

Buy

MA200

0.017

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Ticker SymbolPBMWW

CompanyPsyence Biomedical Ltd

CEODr. Neil Maresky

Website